Allergan, Editas partner on CRISPR tech in eye diseases – FierceBiotech
FierceBiotech |
Allergan, Editas partner on CRISPR tech in eye diseases
FierceBiotech Allergan and gene editing biotech Editas have penned an upfront $90 million CRISPR research pact that will focus on ocular disorders. Under the deal, Allergan gets exclusive access and the option to license up to five of Editas' genome-editing eye … Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseases Editas and Allergan Partner on Multiple CRISPR Eye Disease Programs Editas, Allergan Ink $90M CRISPR-Based Eye Drug Deal |
